Suryaprakash Sambhara

Immunology Head

Centers for Disease Control and Prevention

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Suryaprakash Sambhara serves as the Head of Immunology at the Centers for Disease Control and Prevention in the United States. His research focuses on vaccine development and immunogenicity, particularly in relation to influenza viruses and COVID-19. Recent publications include studies on adenoviral vector-based vaccines and the impact of diabetes on the effectiveness of influenza vaccines among older adults.

Articles (11)

Year:

2025

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Hanne Elyard

Chief Scientific Officer

UNITED STATES

View details

Sara Kim

Emory University

UNITED STATES

View details

Krissy Moehling Geffel

University of Pittsburgh

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Suryaprakash Sambhara

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Adenoviral Vector-Based Vaccine Expressing Hemagglutinin Stem Region with Autophagy-Inducing Peptide Confers Cross-Protection Against Group 1 and 2 Influenza A Viruses

Heterogeneous Ribonucleoprotein A1 (hnRNPA1) Interacts with the Nucleoprotein of the Influenza a Virus and Impedes Virus Replication

Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults

Progress towards the Development of a Universal Influenza Vaccine

Innate lymphoid cells (ILC) in SARS-CoV-2 infection

A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge

Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections

Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized Open-Label Trial

Human Innate Lymphoid Cells in Influenza Infectioand Vaccination

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults

Influenza Virus Infects and Depletes Activated Adaptive Immune Responders

Collaborators (3)

Hanne Elyard

Sara Kim

Krissy Moehling Geffel

Make your next move.